Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203445 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL29400714 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL22552830 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL119444 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL6290889 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL25168212 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL31220290 | 1.00 | MDM4 (0.53) | MDM4TP53IDO1TDO2HDAC1 | |
| SCHEMBL119688 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 | |
| SCHEMBL5967446 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 | |
| SCHEMBL31276348 | 0.93 | MDM4 (0.59) | MDM4TP53KMT2ATLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4404974-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2024-07-31 | — | — | EP | disclosed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230173092-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| EP-4157357-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023047090-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2023-03-30 | — | — | WO | disclosed |
| CN-115666653-A | Antibody-drug conjugates | 斯皮雷亚有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | PCNA, POLI, VIP | MDM4 588/4885TP53 15/4885IDO1 2547/4885 |
| US-20230173092-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | MDM4 2538/4885TP53 787/4885IDO1 2481/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | MDM4 2538/4885TP53 787/4885IDO1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.